LYNPARZA (OLAPARIB) DAWA YA SARATANI: ATHARI MBAYA NA KIPIMO -
Synergistic Effect of Olaparib with Combination of Cisplatin on PTEN-Deficient Lung Cancer Cells | Molecular Cancer Research
DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors - ScienceDirect
Pharmaceutical Capsule - Sutent Capsule Wholesale Trader from Bengaluru
Current Ovarian Cancer Maintenance Strategies and Promising New Developments
Lynparza Olaparib Capsules, Olaparib, Lynparza Olaparib, लिंपारज़ा - MSD PHARMACEUTICALS PRIVATE LIMITED, Mumbai | ID: 20875387333
A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes - European Journal of Cancer
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib - Annals of Oncology
Cancers | Free Full-Text | Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes | HTML
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial - The Lancet Oncology
EP3263095A1 - A pharmaceutical formulation of olaparib - Google Patents
PARP and PARG inhibitors in cancer treatment. - Abstract - Europe PMC
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer | Clinical Cancer Research
Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer: Expert Opinion on Pharmacotherapy: Vol 0, No ja
US OKs 1st drug aimed at women with inherited breast cancer
pCODR EXPERT REVIEW COMMITTEE (pERC) FINAL RECOMMENDATION
Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment (Review)
Olaparib (AZD2281) | ≥99%(HPLC) | Selleck | PARP inhibitor QCFile
PDF) PARP inhibitors in ovarian cancer
OSIMERT 80 MG (OSIMERTINIB) - Saif pharma
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma - EBioMedicine
Genes | Free Full-Text | MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer | HTML
100mg Lynparza Olaparib Tablet, Packaging Type: Bottle, | ID: 21370046230
Oncology Medicines - Olaparib Olanib 50mg Exporter from Mumbai
Olaparib 150 mg Lynparza Tablets | Exporter | Supplier | Distributor
